Loading the library…
system practice & equity
The operative claimChildren in foster care are prescribed psychotropic medications — antipsychotics and multi-drug regimens in particular — at rates several times those of otherwise-comparable Medicaid-enrolled children, including the high-risk practices (concomitant antipsychotics, four-plus-drug polypharmacy) with the least pediatric evidence; state oversight programs measurably reduce this prescribing, which is why federal law requires psychotropic monitoring protocols for children in care.
Researchers, federal auditors, and pediatric bodies agree that children in foster care receive psychotropic medication — antipsychotics and multi-drug regimens especially — at rates far above comparable Medicaid children, that the highest-risk/lowest-evidence practices concentrate in this population, and that oversight programs (prior authorization, utilization review, consultation lines) measurably reduce the prescribing. The genuine debate is aetiological and remedial: how much of the differential is warranted by the population's trauma and psychiatric burden, and how to curb inappropriate regimens without producing undertreatment.
Applies to U.S. children in foster care, measured through Medicaid claims comparisons against non-foster Medicaid populations (TANF-enrolled and disability-qualifying comparison groups), from the 2000s growth era through the post-oversight period. The differential persists after the oversight era bent the overall trend; magnitude varies by state, age, and comparison group.
dosReis S, Yoon Y, Rubin DM, Riddle MA, Noll E, Rothbard A (2011). Antipsychotic Treatment Among Youth in Foster Care. Pediatrics.
Cross-sectional · Medicaid-enrolled children (foster vs comparison groups)
Youth in foster care received antipsychotic medication — including concomitant (two or more simultaneous) antipsychotics — at rates far exceeding TANF-enrolled comparison youth and rivaling or exceeding youth qualifying for Medicaid by disability. Concomitant antipsychotic treatment, a practice with little pediatric evidence base, was concentrated among foster youth. The study that placed foster-care antipsychotic prescribing on the national policy agenda.
Bearing on this claim: Pediatrics claims comparison: foster youth antipsychotic and concomitant-antipsychotic use far exceeds TANF peers, rivals disability-qualifying youth.
doi.org/10.1542/peds.2010-2970Keefe RJ, Van Horne BS, Cain CM, Budolfson K, Thompson R, Greeley CS (2023). Psychotropic Medication Prescribing: Youth in Foster Care Compared with Other Medicaid Enrollees. Journal of Child and Adolescent Psychopharmacology.
Cross-sectional · Medicaid-enrolled children (foster vs non-foster)
Youth in foster care were substantially more likely to be prescribed psychotropic medications than non-foster Medicaid peers, replicating the foster-care prescribing differential in contemporary (post-oversight-era) data. The differential persists a decade after federal monitoring requirements, confirming it is a structural feature of the population and its care systems, not an artifact of one era or state.
Bearing on this claim: Contemporary replication: the foster-care psychotropic differential persists in post-oversight-era Medicaid data.
doi.org/10.1089/cap.2022.0092Davis DW, Lohr WD, Feygin Y, Creel L, Jawad K, Jones VF, Williams PG, Le J, Trace M, Pasquenza N (2021). High-level psychotropic polypharmacy: a retrospective comparison of children in foster care to their peers on Medicaid. BMC Psychiatry.
Cross-sectional · Medicaid-enrolled children (foster vs peers)
Children in foster care were markedly more likely than Medicaid peers to experience high-level psychotropic polypharmacy — four or more concurrent psychotropic medications — and antipsychotic use, the regimens carrying the greatest metabolic and neurological risk with the least pediatric evidence. Documents that the differential is steepest exactly where the safety stakes are highest.
Bearing on this claim: High-level polypharmacy (4+ concurrent psychotropics) markedly concentrated among foster children versus Medicaid peers.
doi.org/10.1186/s12888-021-03309-9Crystal S, Mackie T, Fenton MC, Amin S, Neese-Todd S, Olfson M, Bilder S (2016). Rapid Growth Of Antipsychotic Prescriptions For Children Who Are Publicly Insured Has Ceased, But Concerns Remain. Health Affairs.
Longitudinal · publicly insured U.S. children
The rapid early-2000s growth of antipsychotic prescribing to publicly insured children ceased and partially reversed as states implemented oversight — prior-authorization programs, drug-utilization review, and foster-care-specific monitoring (foster care was the starting point for most initiatives). Evidence that the prescribing differential is policy-responsive; but quality concerns remained, including prescribing without adequate psychosocial services and monitoring.
Bearing on this claim: National trend analysis: antipsychotic growth ceased as state oversight (starting with foster care) took hold; quality concerns remain.
doi.org/10.1377/hlthaff.2016.00644 supporting verified sources
Claims data capture prescriptions filled, not clinical appropriateness — neither over- nor under-treatment can be adjudicated per case from claims alone; foster youth carry genuinely elevated psychiatric need (see trauma-prevalence cards), so no design can fully separate need from systemic drivers; comparison groups differ across studies; and the strongest studies are state-specific, with magnitudes varying by state and era. Long-term outcome data on medicated versus unmedicated foster youth remain thin.